Wikipedia

Empagliflozin: Perbedaan antara revisi

Jelajahi riwayat secara interaktif
← Revisi sebelumnyaRevisi selanjutnya →
Konten dihapus Konten ditambahkan
VisualTeks wiki
WanaraLima (bicara | kontrib)
1.730 suntingan
Artikel baru tentang topik farmasi yang masih memerlukan tambahan dan pengembangan. Artikel ini merupakan terjemahan wikipedia bahasa Inggris masih perlu ditinjau ulang juga disesuaikan dengan padanan bahasa Indonesia
Tag: halaman dengan galat kutipan VisualEditor
Mr. Ibrahem (bicara | kontrib)
49 suntingan
Fix references, Expend infobox mdwiki.toolforge.org.
Baris 9:
<!-- Pharmacokinetic data -->|bioavailability=|protein_bound=|metabolism=|elimination_half-life=|excretion=<!-- Chemical and physical data -->|C=23|Cl=1|H=27|O=7|chemical_formula=|smiles=C1COCC1OC2=CC=C(C=C2)CC3=C(C=CC(=C3)C4C(C(C(C(O4)CO)O)O)O)Cl|StdInChI=1S/C23H27ClO7/c24-18-6-3-14(23-22(28)21(27)20(26)19(11-25)31-23)10-15(18)9-13-1-4-16(5-2-13)30-17-7-8-29-12-17/h1-6,10,17,19-23,25-28H,7-9,11-12H2/t17-,19+,20+,21-,22+,23-/m0/s1|StdInChI_comment=|StdInChIKey=OBWASQILIWPZMG-QZMOQZSNSA-N|molecular_weight=|density=|melting_point=|melting_high=|melting_notes=|boiling_point=|boiling_notes=|solubility=|specific_rotation=}}
 
'''Empagliflozin''' adalah obat yang digunakan digunakan untuk penderita [[Diabetes melitus tipe 2|diabetes tipe 2]], umumnya obat ini digunakan bersamaan dengan diet dan olah raga. <ref name="AHFS2018">{{Cite web|title=Empagliflozin Monograph for Professionals |url=https://www.drugs.com/monograph/empagliflozin.html |website=Drugs.com |publisher=AHFS |access-date=21 December 2018 |archive-date=6 April 2019 |archive-url=https://web.archive.org/web/20190406062958/https://www.drugs.com/monograph/empagliflozin.html |url-status=live }}</ref> <ref name="EU2018">{{Cite journal|date=December 2018|title=Management of hyperglycaemia in type&nbsp;2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)|journal=Diabetologia|volume=61|issue=12|pages=2461–2498|doi=10.1007/s00125-018-4729-5|pmid=30288571|vauthors=Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler DJ, Buse JB}}</ref> Obat ini sendiri kurang diminati jika dibandingkan dengan obat [[metformin]] dan golongan sulfonilurea . <ref name="BNF76">{{Cite book|date=2018|title=British national formulary: BNF 76|publisher=Pharmaceutical Press|isbn=9780857113382|edition=76|pages=691}}</ref> Empagliflozin bisa dikombinasikan dengan obat lainnya seperti metformin atau [[insulin]] . <ref name="AHFS2018">{{cite web |title=Empagliflozin Monograph for Professionals |url=https://www.drugs.com/monograph/empagliflozin.html |website=Drugs.com |publisher=AHFS |access-date=21 December 2018 |archive-date=6 April 2019 |archive-url=https://web.archive.org/web/20190406062958/https://www.drugs.com/monograph/empagliflozin.html |url-status=live }}</ref> <ref name="EU2018">{{cite journal |vauthors=Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler DJ, Buse JB |title=Management of hyperglycaemia in type&nbsp;2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) |journal=Diabetologia |volume=61 |issue=12 |pages=2461–2498 |date=December 2018 |pmid=30288571 |doi=10.1007/s00125-018-4729-5|doi-access=free }}</ref> Empagliflozin sendiri tidak direkomendasikan untuk penderita [[Diabetes melitus tipe 1|diabetes tipe 1]] . <ref name="AHFS2018">{{cite web |title=Empagliflozin Monograph for Professionals |url=https://www.drugs.com/monograph/empagliflozin.html |website=Drugs.com |publisher=AHFS |access-date=21 December 2018 |archive-date=6 April 2019 |archive-url=https://web.archive.org/web/20190406062958/https://www.drugs.com/monograph/empagliflozin.html |url-status=live }}</ref> Rute pemberian obat ini melalui oral. <ref name="AHFS2018">{{cite web |title=Empagliflozin Monograph for Professionals |url=https://www.drugs.com/monograph/empagliflozin.html |website=Drugs.com |publisher=AHFS |access-date=21 December 2018 |archive-date=6 April 2019 |archive-url=https://web.archive.org/web/20190406062958/https://www.drugs.com/monograph/empagliflozin.html |url-status=live }}</ref>
 
Kejadian efek samping yang bisa terjadi selama penggunaan obat ini yakni [[infeksi saluran kemih]], [[mikosis]] pada selangkangan, dan nyeri sendi. <ref name="AHFS2018">{{Cite web|title=Empagliflozin Monograph for Professionals |url=https://www.drugs.com/monograph/empagliflozin.html |website=Drugs.com |publisher=AHFS |access-date=21 December 2018 |archive-date=6 April 2019 |archive-url=https://web.archive.org/web/20190406062958/https://www.drugs.com/monograph/empagliflozin.html |url-status=live }}<cite class="citation web cs1" data-ve-ignore="true">[https://www.drugs.com/monograph/empagliflozin.html "Empagliflozin Monograph for Professionals"]. ''Drugs.com''. AHFS. [https://web.archive.org/web/20190406062958/https://www.drugs.com/monograph/empagliflozin.html Archived] from the original on 6 April 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">21 December</span> 2018</span>.</cite></ref> Kejadian efek samping yang lebih jarang namun cukup serius yakni infeksi kulit pada [[selangkangan]] yang disebut [[gangren Fournier]] dan suatu bentuk [[ketoasidosis diabetik]] dengan kadar gula darah normal. <ref name="AHFS2018">{{cite web |title=Empagliflozin Monograph for Professionals |url=https://www.drugs.com/monograph/empagliflozin.html |website=Drugs.com |publisher=AHFS |access-date=21 December 2018 |archive-date=6 April 2019 |archive-url=https://web.archive.org/web/20190406062958/https://www.drugs.com/monograph/empagliflozin.html |url-status=live }}</ref> <ref name="FDA2019SE">{{Cite web|date=2019-02-09|title=FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes|url=https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-rare-occurrences-serious-infection-genital-area-sglt2-inhibitors-diabetes|website=U.S. [[Food and Drug Administration]] (FDA)|archive-url=https://web.archive.org/web/20191213201737/https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-rare-occurrences-serious-infection-genital-area-sglt2-inhibitors-diabetes|archive-date=13 December 2019|access-date=2019-03-18|url-status=live}}</ref> Ibu hamil tidak direkomendasikan untuk menggunakan obat ini. <ref name="BNF76">{{Cite book|date=2018|title=British national formulary: BNF 76|publisher=Pharmaceutical Press|isbn=9780857113382|edition=76|pages=691}}<cite class="citation book cs1" data-ve-ignore="true">''British national formulary: BNF 76'' (76&nbsp;ed.). </cite></ref> Penderita [[nefropati]] tidak direkomendasikan menggunakan obat ini walaupun bisa membantu memperlambat perkembangan masalah ginjal ringan. <ref name="AHFS2018">{{cite web |title=Empagliflozin Monograph for Professionals |url=https://www.drugs.com/monograph/empagliflozin.html |website=Drugs.com |publisher=AHFS |access-date=21 December 2018 |archive-date=6 April 2019 |archive-url=https://web.archive.org/web/20190406062958/https://www.drugs.com/monograph/empagliflozin.html |url-status=live }}</ref> <ref name="EU2018">{{Cite journal|date=December 2018|title=Management of hyperglycaemia in type&nbsp;2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)|journal=Diabetologia|volume=61|issue=12|pages=2461–2498|doi=10.1007/s00125-018-4729-5|pmid=30288571|vauthors=Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler DJ, Buse JB}}<cite class="citation journal cs1" data-ve-ignore="true" id="CITEREFDaviesD'AlessioFradkinKernan2018">Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler DJ, Buse JB (December 2018). </cite></ref> Empagliflozin merupakan penghambat ko-transporter natrium glukosa-2 (SGLT-2), dan memiliki mekanisme kerja dengan cara meningkatkan gula yang hilang di dalam [[Urine|urin]] . <ref name="AHFS2018">{{cite web |title=Empagliflozin Monograph for Professionals |url=https://www.drugs.com/monograph/empagliflozin.html |website=Drugs.com |publisher=AHFS |access-date=21 December 2018 |archive-date=6 April 2019 |archive-url=https://web.archive.org/web/20190406062958/https://www.drugs.com/monograph/empagliflozin.html |url-status=live }}</ref>
 
Obat empagliflozin sudah disetujui untuk penggunaan secara medis di Amerika Serikat dan di Uni Eropa pada tahun 2014. <ref name="AHFS2018">{{Cite web|title=Empagliflozin Monograph for Professionals |url=https://www.drugs.com/monograph/empagliflozin.html |website=Drugs.com |publisher=AHFS |access-date=21 December 2018 |archive-date=6 April 2019 |archive-url=https://web.archive.org/web/20190406062958/https://www.drugs.com/monograph/empagliflozin.html |url-status=live }}<cite class="citation web cs1" data-ve-ignore="true">[https://www.drugs.com/monograph/empagliflozin.html "Empagliflozin Monograph for Professionals"]. ''Drugs.com''. AHFS. [https://web.archive.org/web/20190406062958/https://www.drugs.com/monograph/empagliflozin.html Archived] from the original on 6 April 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">21 December</span> 2018</span>.</cite></ref> <ref name="FDA Approval">{{Cite web|date=8 September 2014|title=Drug Approval Package: Jardiance (empagliflozin) Tablets NDA #204629|url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204629Orig1s000TOC.cfm|website=U.S. [[Food and Drug Administration]] (FDA)|archive-url=https://web.archive.org/web/20200211052628/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204629Orig1s000TOC.cfm|archive-date=11 February 2020|access-date=10 February 2020|url-status=live}}</ref> <ref>{{Cite web|title=Jardiance: FDA-Approved Drugs|url=https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204629|website=U.S. [[Food and Drug Administration]] (FDA)|archive-url=https://web.archive.org/web/20200211052643/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204629|archive-date=11 February 2020|access-date=10 February 2020|url-status=live}}</ref> <ref name="Jardiance EPAR">{{Cite web|title=Jardiance EPAR|url=https://www.ema.europa.eu/en/medicines/human/EPAR/jardiance|website=[[European Medicines Agency]] (EMA)|archive-url=https://web.archive.org/web/20210828073439/https://www.ema.europa.eu/en/medicines/human/EPAR/jardiance|archive-date=28 August 2021|access-date=10 February 2020|url-status=live}}</ref> Obat ini masuk ke dalam [[Daftar Obat Esensial Organisasi Kesehatan Dunia]] . <ref name="WHO23rd">{{Cite book|vauthors=((World Health Organization))|year=2023|title=The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023)|location=Geneva|publisher=World Health Organization|hdl=10665/371090|id=WHO/MHP/HPS/EML/2023.02|author-link=World Health Organization|hdl-access=free}}</ref>
 
== Referensi ==
Diperoleh dari "https://wiki-indonesia.club/wiki/Empagliflozin"